SCHEMBL27248907

SCHEMBL27248907

CC(C)(C)NC(=O)COc1cccc(-c2nc(Nc3ccc(N4CCOCC4)nc3)c3sccc3n2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 2/20 0.51
▸ HDAC4 P56524 2/20 0.51
▸ HDAC1 Q13547 2/20 0.51
▸ HDAC7 Q8WUI4 2/20 0.51
▸ HDAC2 Q92769 2/20 0.51
▸ HDAC10 Q969S8 2/20 0.51
▸ HDAC11 Q96DB2 2/20 0.51
▸ HDAC8 Q9BY41 2/20 0.51
▸ HDAC6 Q9UBN7 2/20 0.51
▸ HDAC9 Q9UKV0 2/20 0.51
▸ HDAC5 Q9UQL6 2/20 0.51
▸ SLC2A1 P11166 12/20 0.50
▸ SLC2A3 P11169 12/20 0.50
▸ SYK P43405 1/20 0.43
▸ ROCK2 O75116 2/20 0.43
▸ PIK3CA P42336 2/20 0.41
▸ MTOR P42345 1/20 0.41
▸ ROCK1 Q13464 1/20 0.41
▸ PIK3C2B O00750 1/20 0.41
▸ CCNE2 O96020 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27248662 0.94 SLC2A1 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL27249014 0.92 SLC2A1 (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL27248607 0.92 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL27248796 0.90 ROCK2 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL27249066 0.88 ROCK2 (0.52) SLC2A1SLC2A3ROCK2ROCK1
SCHEMBL31173601 0.86 SLC2A1 (0.53) SLC2A1SLC2A3SYKROCK2ROCK1
SCHEMBL27248949 0.86 SLC2A1 (0.53) SLC2A1SLC2A3SYKROCK2ROCK1
SCHEMBL27248739 0.85 SLC2A1 (0.49) SLC2A1SLC2A3SYKROCK2ROCK1
SCHEMBL27248864 0.85 SLC2A1 (0.49) SLC2A1SLC2A3ROCK2ROCK1
SCHEMBL27248767 0.84 SLC2A1 (0.51) SLC2A1SLC2A3SYKMTORDGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360085-A1 Glucose Uptake Inhibitors KADMON CORPORATION, LLC (US) 2024-10-31 — — US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 — — US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 — — US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 — — US disclosed
US-20220363648-A1 Glucose Uptake Inhibitors KADMON CORPORATION, LLC 2022-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030857-B2 Glucose uptake inhibitors SLC2A1, SLC2A4, SLC2A2 HDAC3 1047/4885HDAC4 556/4885HDAC1 932/4885
US-20220363648-A1 Glucose Uptake Inhibitors SLC2A1, SLC2A4, SLC2A2 HDAC3 1047/4885HDAC4 556/4885HDAC1 932/4885
US-20240360085-A1 Glucose Uptake Inhibitors SLC2A3, SLC2A1, SLC2A4 HDAC3 846/4885HDAC4 549/4885HDAC1 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback